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Correction to: Orphanet Journal of Rare Diseases 15,
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https://doi.org/10.1186/s13023-020-01379-8
Following the original article's publication [1] the
authors asked for the correction of Fig. 2, since the
names of the disease genes [GCH1 and PCBD1] in
the figure published did not match the listed diseases
[AR-GTPCHD and PCDD]. The correct Fig. 2 is
shown below:
In the context of the manuscript correction and in
order to match the text content, the words "apart from
DHPRD" should be removed from the second row and
second column of Table 4, as shown below:
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Fig. 2 (See legend on next page.)
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Fig. 2 Diagnostic flowchart for differential diagnosis of BH4Ds with and without HPA.
1Consider genetic HPA workup depending on availability
and financial resources. The gene panel should include the QDPR, GCH1, PTS PCBD1, SPR genes as well as DNAJC12. For GCH1, consider MLPA if
Sanger sequencing is negative. 2The analysis in urine is more sensitive than in DBS and pathological patterns suggestive for PCDD and SRD can
only be detected in urine but not in DBS. 3Primapterin measurement in urine is only elevated in PCDD. 4Aminoacids in CSF are not required for
diagnosis of BH4Ds.
5CSF analysis should always include standard measurements (cell count, proteins, glucose and lactate). 6Recommendation
against measurements of HVA, 5-HIAA, 5-MTHF, and pterins in CSF in the case of PCDD. (*) A diagnostic L-Dopa trial should be limited to children
with symptoms suggestive of dopa-responsive dystonia or to situations where biochemical and genetic diagnostic tools are not available. If the
diagnostic L-Dopa trial is positive but the results of CSF biochemical and/or molecular genetic testing are not compatible with AD-GTPCHD or
SRD, further aetiologies for dopa responsive dystonia should be considered (e.g. juvenile parkinsonism (PARK2gene)). (**) Can be considered if
available. See text for more detailed information. Abbreviations: 5-HIAA, 5-hydroxyindoleacetic acid; 5-MTHF, 5-methyltetrahydrofolate; AA: amino
acids; AD−/AR- GTPCHD: guanosine triphosphate cyclohydrolase I deficiency; BH4, tetrahydrobiopterin; Bio: biopterin; CSF: cerebrospinal fluid; DBS:
dry blood spot; DHPR: q-dihydropteridine reductase; DHPRD, dihydropteridine reductase deficiency; HVA, homovanillic acid; MRI, magnetic
resonance imaging; N: normal; NBS: newborn screening; Neo: neopterin; NR: not reported; PAH: phenylalanine hydroxylase; Phe: phenylalanine;
PKU: phenylketonuria; Prim: primapterin; PTPSD, 6-pyruvoyltetrahydropterin synthase deficiency; SRD: sepiapterin reductase deficiency; Tyr:
tyrosine; u: urine; (+) = positive effect; (−) = no or no clear effect
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Table 4 Recommended drugs and doses for BH4 disorders











Follow PKU national treatment
recommendations
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In young infants at least as many
































5-HTP should follow L-Dopa/DCI
treatment initiation
Always in combination with a
peripheral decarboxylase inhibitor
(for example by simultaneous
application with L-Dopa/DC
inhibitor)






































(3.3 mg/d base / 4
mg/d salt)
Increase































Children > 12 years




















Can cause sleep disturbances –
morning and afternoon or
lunchtime dosage is possible
ATTENTION: orally disintegrating
preparation needs much less
dosage because the first-pass ef-
fect of the liver is avoided
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Table 4 Recommended drugs and doses for BH4 disorders (Continued)









< 15 kg: start 0.5–
1mg/day














< 15 kg BW
30mg/day




by 1–2 mg/d in
2–4 doses/d
Consider side effects: like dry
mouth, dry
























> 12 years: 50

















days to 50 mg/
day
in 1 dose
> 12 years 50
mg/day in 1
dose
Don’t stop treatment suddenly
Note: Elevated risk of serotonin
syndrome
(SS) or malignant neuroleptic
syndrome (MNS) when used with
drugs impacting serotonergic







5–8 mg/day Slow release preparation for sleep-
maintenance insomnia available in
some countries
Please note: The doses given are in a range typically used and have been published. In individual patients, some adjustment may be necessary depending on
symptom response and side effects
aThe evaluated literature did not provide BH4D specific treatment dose recommendations for this drug. The listed doses, therefore, indicate treatment
recommendations from Summary of Product Characteristics (SmPC) or neurotransmitter related publications (e.g. [119])
Abbreviations: 5-HIAA 5-hydroxyindoleacetic acid, 5-HTP 5-hydroxytryptophan, 5-MTHF 5- methyltetrahydrofolate, HVA Homovanillic acid, AD-GTPCHD Autosomal-
dominant guanosine triphosphate cyclohydrolase I deficiency, BH4D Tetrahydrobiopterin deficiency, BW Body weight, COMT Catechol-O-methyl transferase, CSF
Cerebrospinal fluid, DBS Dry blood spot, DC Decarboxylase, DCI Decarboxylase inhibitor, DHPRD Dihydropteridine reductase deficiency, L-Dopa L-3,4-
dihydroxyphenylalanine, MAO B Monoamine oxidase B, PCDD Pterin-4-alpha-carbinolamine dehydratase deficiency, Phe Phenylalanine, PKU Phenylketonuria, SSRI
Selective serotonin reuptake inhibitor
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